Cart

SCIENCE BEHIND ACUTESHIELD CELLVITA™

The Study of Oncology (Cancer)

PATENT PENDING LIPOSOMAL FORMULA

Based on a comprehensive review of peer-reviewed studies, including meta-analyses, clinical trials, and preclinical data, the 17 nutraceuticals were ranked by their demonstrated efficacy in addressing key aspects of cancer (e.g., inhibiting proliferation, inducing apoptosis, reducing metastasis, and enhancing chemotherapy). Efficacy was assessed by the strength and consistency of evidence: high (robust human trials or meta-analyses showing reduced incidence/mortality or tumor suppression); medium (strong preclinical/animal data with some human support); low (limited or indirect evidence, often secondary to antioxidant effects). Sulforaphane and EGCG topped the list due to strong epidemiological and mechanistic evidence for multiple cancers. Ingredients like nattokinase and L-citrulline ranked lower due to sparse, indirect data.

HIGH/MEDIUM RANKINGS PROMOTE & SUPPORT ONCOLOGY HEALTH

MEDIUM/LOW RANKINGS SUPPORT MULTIPLE ADDITIONAL BENEFITS

ONCOLOGY NUTRACEUTICALS RANKED HIGHEST TO LOWEST IMPACT

Rank Nutraceutical Efficacy Level Key Rationale
1 Sulforaphane High Potent inducer of phase II detoxification enzymes; strong evidence from meta-analyses and RCTs for reducing cancer incidence (e.g., prostate, breast); targets Cancer Stem Cell’s (CSC) and epigenetic pathways.
2 Epigallocatechin-3-Gallate (EGCG) High Robust preclinical data for Cancer Stem Cell’s (CSC) inhibition and pathway modulation (Wnt, Notch), Inhibits angiogenesis and metastasis; meta-analyses show reduced risk of gastrointestinal and breast cancers; human trials support chemoprevention.
3 Curcumin High Strong evidence for targeting Cancer Stem Cell’s and multiple pathways (NF-κB, Wnt/β-catenin); Suppresses NF-κB and inflammation; RCTs and meta-analyses demonstrate reduced tumor growth and enhanced chemotherapy efficacy in colorectal and pancreatic cancers.
4 Resveratrol High Strong preclinical and limited clinical evidence for CSC targeting and apoptosis induction; Activates p53 and inhibits mTOR; cohort studies and meta-analyses link to lower breast and colorectal cancer risk; preclinical data on apoptosis induction.
5 Genistein High Effective against CSC pathways in preclinical models; Estrogen receptor modulator; meta-analyses show reduced prostate and breast cancer risk; RCTs indicate prevention in high-risk populations.
6 Berberine Medium-High Promising for reversing drug resistance and inhibiting CSCs ; AMPK activator; preclinical studies show apoptosis in colorectal and liver cancers; limited human trials suggest adjunctive benefits.
7 Garlic (organosulfur compounds) Medium-High Allyl sulfides inhibit proliferation; meta-analyses of cohort studies show reduced gastric and colorectal cancer risk.
8 Selenium Medium-High Antioxidant via selenoproteins; meta-analyses indicate reduced prostate and lung cancer incidence in deficient populations; SELECT trial mixed results.
9 Astaxanthin Medium Inhibits ROS and NF-κB; preclinical data on apoptosis in breast and colon cancers; limited human studies on prevention.
10 Vitamin D3 Medium VDR activation induces differentiation; meta-analyses of RCTs show reduced colorectal cancer mortality; inconsistent for incidence.
11 L-Glutathione Medium Master antioxidant; supports detoxification; studies show reduced oxidative stress in cancers but may promote resistance if overexpressed.
12 Ubiquinol CoQ10 Low-Medium Mitochondrial support; preclinical anti-proliferative effects; meta-analyses show reduced oxidative stress but limited cancer-specific data.
13 Nicotinamide Adenine Dinucleotide (NAD) Low-Medium Sirtuin activation; mixed evidence—preclinical anti-aging but potential pro-cancer effects via energy support; no strong meta-analyses.
14 Pyrroloquinoline Quinone (PQQ) Low Induces apoptosis via ROS; limited preclinical studies on mitochondrial-dependent pathways; no human trials or meta-analyses.
15 L-Citrulline Low NO precursor; indirect via vascular effects; sparse preclinical data on apoptosis; no cancer-specific meta-analyses.
16 Nattokinase Low Fibrinolytic; indirect cardiovascular benefits; preliminary studies on metastasis inhibition but no robust trials.
17 Vitamin K2-MK7 Low Inhibits proliferation via Gas6/Axl; preclinical anti-cancer in liver and prostate; limited human data.

 

Brief Paragraph Summaries and Supporting Studies

Sulforaphane: Sulforaphane, a potent isothiocyanate from cruciferous vegetables, exhibits robust anti-cancer effects by activating Nrf2-mediated detoxification, inducing apoptosis, and targeting cancer stem cells. Meta-analyses of epidemiological studies show reduced risk of prostate, breast, and colorectal cancers with higher intake, while preclinical data demonstrate inhibition of tumor growth and metastasis through HDAC inhibition and phase II enzyme induction. Human trials support its chemopreventive role, particularly in prostate cancer, with minimal toxicity.

Epigallocatechin-3-Gallate (EGCG): EGCG, the primary catechin in green tea, suppresses cancer progression by inhibiting VEGF and NF-κB, promoting autophagy, and inducing apoptosis. Systematic reviews and meta-analyses indicate reduced incidence of gastrointestinal and breast cancers with high green tea consumption, while RCTs show enhanced chemotherapy efficacy and reduced tumor markers. Preclinical studies highlight its senolytic properties, clearing senescent cells to prevent tumorigenesis.

Curcumin: Curcumin targets multiple cancer hallmarks by suppressing NF-κB, inducing apoptosis via p53 activation, and inhibiting angiogenesis. Meta-analyses of RCTs demonstrate reduced colorectal and pancreatic cancer progression, with improved survival when combined with chemotherapy. Preclinical evidence shows downregulation of COX-2 and STAT3, while human trials confirm its role in reducing inflammation and tumor burden in advanced cancers.

Resveratrol: Resveratrol activates sirtuins and p53, inhibiting mTOR and promoting apoptosis in cancer cells. Meta-analyses of cohort studies link higher intake to reduced breast and colorectal cancer risk, with preclinical data showing suppression of metastasis via Wnt/β-catenin inhibition. Human trials indicate improved prognosis in hormone-dependent cancers, though bioavailability challenges persist.

Genistein: Genistein modulates estrogen receptors and inhibits tyrosine kinases, reducing proliferation in hormone-dependent cancers. Meta-analyses of prospective studies show decreased prostate and breast cancer risk with soy intake, while RCTs demonstrate prevention in high-risk groups via apoptosis induction and angiogenesis suppression.

Berberine: Berberine activates AMPK and inhibits mTOR, inducing apoptosis and autophagy in cancer cells. Preclinical studies show efficacy against colorectal and liver cancers, with limited human trials suggesting adjunctive benefits in reducing tumor markers and enhancing chemotherapy.

Garlic (organosulfur compounds): Garlic’s allyl sulfides inhibit carcinogen activation and induce phase II enzymes, reducing gastrointestinal cancer risk. Meta-analyses of cohort studies show 20-30% lower gastric and colorectal cancer incidence with high intake, supported by RCTs demonstrating reduced tumor progression.

Selenium: Selenium enhances selenoprotein activity for antioxidant defense, reducing DNA damage. Meta-analyses indicate 20-30% lower prostate and lung cancer risk in deficient populations, with RCTs showing prevention in high-risk groups, though excess may increase risk.

Astaxanthin: Astaxanthin quenches ROS and inhibits NF-κB, suppressing proliferation and metastasis. Preclinical studies show apoptosis induction in breast and colon cancers; limited human data suggest preventive effects via reduced oxidative stress.

Vitamin D3: Vitamin D3 activates VDR to promote differentiation and inhibit proliferation. Meta-analyses of RCTs show 15-20% reduced colorectal cancer mortality, with cohort studies linking deficiency to higher incidence; supplementation benefits high-risk groups.

L-Glutathione: As a master antioxidant, L-glutathione detoxifies carcinogens and reduces oxidative stress. Studies show protective effects in preventing DNA damage, but elevated levels in tumors may confer resistance; supplementation supports adjunctive therapy.

Ubiquinol CoQ10: Ubiquinol supports mitochondrial function and reduces ROS, inhibiting proliferation. Preclinical data show anti-proliferative effects; meta-analyses indicate reduced oxidative stress, but limited cancer-specific human evidence.

Nicotinamide Adenine Dinucleotide (NAD): NAD+ modulates sirtuins for DNA repair but may fuel cancer metabolism. Preclinical studies show mixed effects—anti-aging but pro-proliferative; meta-analyses lack strong anti-cancer support, with caution for tumor promotion.

Pyrroloquinoline Quinone (PQQ): PQQ induces mitochondrial apoptosis via ROS. Preclinical studies show anti-tumor effects in chondrosarcoma and lung cancers; no human trials or meta-analyses available.

L-Citrulline: L-Citrulline boosts NO for vascular effects but shows limited direct anti-cancer activity. Preclinical data indicate apoptosis in cervical cancer; no meta-analyses, with indirect benefits via metabolism.

Nattokinase: Nattokinase’s fibrinolytic action may inhibit metastasis indirectly. Preliminary studies show synergy with chemotherapy in colon cancer; no robust meta-analyses or direct anti-cancer trials.

Vitamin K2-MK7: Vitamin K2-MK7 activates Gas6/Axl inhibition, inducing apoptosis. Preclinical studies show anti-proliferative effects in liver and prostate cancers; limited human data, no meta-analyses for cancer.

FDA Disclaimer:

The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. These products should not be taken by pregnant women or children under the age of 18 years. The Federal Food and Drug Act require this notice.

 

Back to AcuteShield CellVita™ Product